Glioblastoma (GBM) is the most aggressive primary malignancy of the central nervous system, characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. A major contributor to its dismal clinical outcome is the highly invasive nature of glioblastoma cells, which infiltrate surrounding healthy brain parenchyma, precluding complete surgical resection and promoting therapeutic resistance. Emerging evidence suggests that the gut microbiota influences glioblastoma progression via modulation of neurotransmitter signaling and immune responses, and through alteration of microbial composition and metabolite production that impact tumor development. Building on our prior work demonstrating the relevance of the gut-brain axis in both physiological and glioma contexts, we identified a significant reduction in fecal levels of 3-hydroxy-3-methylbutyrate (3H3MB), a gut-associated leucine-derived metabolite that is chemically and metabolically distinct from the short-chain fatty acid butyrate, in glioma-bearing mice relative to their pre-tumor state. Given that 3H3MB administration has been reported to attenuate growth and proliferation in carcinoma models, we investigated its potential anti-tumor effects in glioma. In vivo, oral gavage of 3H3MB to glioma-bearing mice resulted in a significant reduction in tumor volume, decreased cellular proliferation, and prolonged overall survival compared to control animals. In vitro, 3H3MB markedly inhibited the proliferation of mouse glioma and human glioblastoma cell lines, modulating cell cycle phases; moreover, the treatment suppressed glioma cell migration and serum-induced invasion. These findings suggest that 3H3MB exerts robust anti-tumor effects in glioma-bearing mice and holds promise as a novel metabolic therapy for glioblastoma, supported by its established clinical evaluation in other pathological conditions.

3-hydroxy-3-methylbutyrate (3H3MB) suppresses glioma growth and extends survival in mice / Khan, R., Lin, X., Marrocco, F., Giampaoli, O., Reccagni, A., Maqbool, J., Sciubba, F., Patriarca, A., De Rosa, M., Miccheli, A., Favaretto, G., Antonangeli, F., Limatola, C., D'Alessandro, G.. - In: FRONTIERS IN MOLECULAR NEUROSCIENCE. - ISSN 1662-5099. - 19:(2026). [10.3389/fnmol.2026.1917452]

3-hydroxy-3-methylbutyrate (3H3MB) suppresses glioma growth and extends survival in mice

Khan, Rizwan
Primo
Investigation
;
Lin, Xingzi
Investigation
;
Giampaoli, Ottavia
Investigation
;
Reccagni, Alice
Investigation
;
Maqbool, Javeria
Investigation
;
Sciubba, Fabio
Formal Analysis
;
Patriarca, Adriano
Formal Analysis
;
De Rosa, Michele
Formal Analysis
;
Miccheli, Alfredo
Formal Analysis
;
Antonangeli, Fabrizio
Investigation
;
Limatola, Cristina
Penultimo
Resources
;
D'Alessandro, Giuseppina
Ultimo
Supervision
2026

Abstract

Glioblastoma (GBM) is the most aggressive primary malignancy of the central nervous system, characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. A major contributor to its dismal clinical outcome is the highly invasive nature of glioblastoma cells, which infiltrate surrounding healthy brain parenchyma, precluding complete surgical resection and promoting therapeutic resistance. Emerging evidence suggests that the gut microbiota influences glioblastoma progression via modulation of neurotransmitter signaling and immune responses, and through alteration of microbial composition and metabolite production that impact tumor development. Building on our prior work demonstrating the relevance of the gut-brain axis in both physiological and glioma contexts, we identified a significant reduction in fecal levels of 3-hydroxy-3-methylbutyrate (3H3MB), a gut-associated leucine-derived metabolite that is chemically and metabolically distinct from the short-chain fatty acid butyrate, in glioma-bearing mice relative to their pre-tumor state. Given that 3H3MB administration has been reported to attenuate growth and proliferation in carcinoma models, we investigated its potential anti-tumor effects in glioma. In vivo, oral gavage of 3H3MB to glioma-bearing mice resulted in a significant reduction in tumor volume, decreased cellular proliferation, and prolonged overall survival compared to control animals. In vitro, 3H3MB markedly inhibited the proliferation of mouse glioma and human glioblastoma cell lines, modulating cell cycle phases; moreover, the treatment suppressed glioma cell migration and serum-induced invasion. These findings suggest that 3H3MB exerts robust anti-tumor effects in glioma-bearing mice and holds promise as a novel metabolic therapy for glioblastoma, supported by its established clinical evaluation in other pathological conditions.
2026
3H3MB or β-hydroxy-β-methylbutyrate; glioblastoma; gut microbiota; gut-brain axis; tumor cell invasion; tumor cell proliferation
01 Pubblicazione su rivista::01a Articolo in rivista
3-hydroxy-3-methylbutyrate (3H3MB) suppresses glioma growth and extends survival in mice / Khan, R., Lin, X., Marrocco, F., Giampaoli, O., Reccagni, A., Maqbool, J., Sciubba, F., Patriarca, A., De Rosa, M., Miccheli, A., Favaretto, G., Antonangeli, F., Limatola, C., D'Alessandro, G.. - In: FRONTIERS IN MOLECULAR NEUROSCIENCE. - ISSN 1662-5099. - 19:(2026). [10.3389/fnmol.2026.1917452]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1781997
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact